News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
mexc.co Market update
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
Needham has revised its target price for Collegium Pharmaceutical Inc (NASDAQ: COLL) downwards from $56 to $46. This article, published on August 7th, highlights the analyst's updated outlook on the pharmaceutical company.
Collegium Pharmaceutical announced an Accelerated Share Repurchase agreement with Jefferies LLC to buy back $50 million of its common stock. This action is part of a larger $150 million share repurchase program authorized in July 2025, leaving $100 million remaining after this transaction. The …
Collegium Pharmaceutical has entered into an Accelerated Share Repurchase agreement with Jefferies LLC to buy back $50 million of its common stock, part of a larger $150 million share repurchase program. The company will receive an initial delivery of 1,556,420 shares, representing about 80% …
Image source: The Motley Fool. DATE Thursday, Aug. 6, 2026 at 8:00 a.m. ET CALL PARTICIPANTS Head of Investor Relations - Ian Karp President and Chief Executive Officer - Vikram Karnani Chief Financial Officer - Colleen Tupper Full Conference Call Transcript Operator: Greetings, and …
Collegium Pharmaceutical (COLL) saw its stock rise in premarket trading after announcing an accelerated share repurchase agreement with Jefferies (JEF) to buy back $50 million of its company stock. This accelerated buyback is part of a larger $150 million share repurchase program authorized by …
Collegium Pharmaceutical has initiated a $50 million accelerated share repurchase (ASR) program with Jefferies, receiving an initial 1,556,420 shares. This ASR is part of a larger $150 million board-authorized buyback program, with the final share count to be determined by the volume-weighted average price …
Collegium Pharmaceutical, Inc. announced an Accelerated Share Repurchase (ASR) agreement with Jefferies LLC to repurchase $50 million of its common stock. This ASR is part of a larger $150 million share repurchase program, leaving $100 million remaining after this transaction. The company believes its …
Collegium Pharmaceutical's Q2 earnings showed sales growth driven by its ADHD business, with Jornay PM revenue up 41% year-over-year, but overall revenue missed Wall Street estimates due to pricing pressure on the NUCYNTA pain franchise. Despite this, the company raised its full-year revenue guidance. …
Colliers International Group Inc (CIGI) shares rose 3.5% to $103.63, significantly below its GF Value™ estimate of $150.06, indicating it is undervalued by 30.9%. The company has a GF Score™ of 74/100, driven by strong growth prospects (9/10), but tempered by concerns in financial …
Grove Collaborative Holdings Inc. (NYSE:GROV) has received a notice from the New York Stock Exchange for non-compliance with listing standards. The company failed to meet the requirement of an average global market capitalization of at least $50 million and stockholders' equity of at least …
MIAMI, Aug. 11, 2026 /CNW/ -- Collective Mining Ltd. (NASDAQ: CNL) (TSX: CNL) ("Collective" or the "Company") is pleased to announce that its common shares will commence trading today on the Nasdaq Global Select Market® ("Nasdaq") under the symbol "CNL".NASDAQ TSX CNL Logo Color …
Colliers International Group Inc. (NASDAQ:CIGI) has received a "Moderate Buy" consensus rating from analysts, with an average 12-month price target of $157.56, significantly above its current price of $100.08. Despite beating quarterly EPS estimates at $1.83, revenue of $1.38 billion fell short of forecasts, …
Sharemaestro market context Price below Trend Line 52 weeks -36.9% · Next-week setup positive 61.7%Grove Collaborative Holdings (NYSE:GROV) released its quarterly results, with revenues meeting analyst predictions and statutory losses being smaller than expected. Despite a forecast for increased losses next year and expected revenue decline compared to the industry, the analyst lifted the price target by 33% …
Collegium Pharmaceutical (COLL) missed Q2 CY2026 revenue expectations but beat non-GAAP profit estimates, with sales increasing 6.3% year-on-year. The company's revenue guidance for the full year was lifted, primarily due to strong performance in its ADHD business, particularly Jornay PM and the integration of …
Sei Investments Co. significantly increased its stake in Collegium Pharmaceutical, Inc. ($COLL) by 191.6% in the first quarter, acquiring 85,830 additional shares, bringing its total holding to 130,620 shares valued at approximately $4.32 million. Other institutional investors also adjusted their positions, with Jennison Associates …
Collegium Pharmaceutical, Inc. (NASDAQ: COLL) generated $780.57 million USD in revenue last year, primarily from its Pharmaceutical segment. This marks an increase from the previous year's $631.45 million USD, with the United States being the sole contributor to this revenue. The financial data highlights …
Collegium Pharmaceutical (COLL) experienced a 1.2% stock increase after Q2 earnings, despite swinging from a profit to a net loss of US$15.1 million. While revenue grew to US$199.9 million, driven by its ADHD portfolio, the company faced a significant margin squeeze due to acquisition …
Wall Street Zen has downgraded Collegium Pharmaceutical (NASDAQ:COLL) from "Buy" to "Hold," leading to mixed analyst views but a consensus "Moderate Buy" rating with an average price target of $52.60. Despite exceeding Q2 earnings expectations with strong ADHD portfolio growth, the company lowered its …
Collegium Pharmaceutical (NASDAQ:COLL) announced quarterly earnings that surpassed analyst estimates, reporting $1.92 EPS against a consensus of $1.72, and revenue of $199.88 million. The company experienced strong growth in its ADHD portfolio, particularly with JORNAY PM and the recent AZSTARYS acquisition, but faced declines …
Grove Collaborative Holdings Inc (GROV) has an earnings forecast score of 8.00 and an average analyst price target of $2.00, representing a 78.57% upside. Analysts mostly recommend a "Buy" for GROV stock, with an expected revenue of $37.30M for the next quarter and an …
Grove Collaborative Holdings reported a smaller-than-expected loss of -$0.03 per share in Q2 2026, beating analyst estimates, but its revenue of $36.56 million fell short of forecasts. Despite a 1% sequential revenue increase and a third consecutive quarter of positive Adjusted EBITDA, the company …
Grove Collaborative Holdings (NYSE: GROV) reported a Q2 EPS of $-0.030, exceeding analyst estimates by $0.04, but revenue of $36.56M fell short of the $45.61M consensus. The company also provided FY 2026 revenue guidance of $142.500M-$152.500M, against an analyst consensus of $148.800M. The stock …
Search by ticker symbol or company name and select a result to open its chart.